What are the recent trends in market size and growth for the addison’s disease market?
The addison’s disease market size has grown rapidly in recent years. It will grow from $2.05 billion in 2024 to $2.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to rising incidences of Addison’s disease globally, increasing awareness regarding adrenal insufficiency, growth in healthcare expenditure, rising prevalence of autoimmune diseases, and growing geriatric population.
The addison’s disease market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing demand for advanced therapeutics, increasing focus on early diagnosis, rising prevalence of congenital adrenal hyperplasia cases, growth of telemedicine services, and rising incidence of adrenal tuberculosis. Major trends in the forecast period include advancements in laboratory testing methodologies, advancements in hormone replacement therapies, advancements in imaging technologies, the development of long-acting injectable formulations, and the integration of artificial intelligence in diagnostic tools.
Get Your Free Sample of The Global Addison’s Disease Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21084&type=smp
How have varous drivers impacted the growth of the addison’s disease market?
The growing prevalence of autoimmune diseases is expected to propel the growth of the addison’s disease market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy tissues, leading to inflammation and damage. Genetic predispositions, environmental factors like pollutants and dietary changes, and lifestyle influences like stress and lack of physical activity all contribute to the growing prevalence of autoimmune diseases. The growing prevalence of autoimmune diseases is increasing the likelihood of co-occurrence with Addison’s disease, as many patients develop additional autoimmune conditions. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based organization, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. This is higher than earlier estimates of 3% to 9%. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the addison’s disease market.
What are the primary segments of the addison’s disease market?
The addison’s disease market covered in this report is segmented –
1) By Type: Primary Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal Insufficiency
2) By Drug Class: Oral Corticosteroid, Hydrocortisone, Fludrocortisone, Corticosteroid Injections
3) By Diagnosis: Laboratory Testing, Imaging Testing
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Primary Adrenal Insufficiency: Autoimmune Addison’s Disease, Infectious Addison’s Disease, Other causes of primary adrenal insufficiency
2) By Secondary Adrenal Insufficiency: Pituitary gland dysfunction, Hypothalamic dysfunction
3) By Tertiary Adrenal Insufficiency: Hypothalamic or pituitary suppression due to long-term steroid use, Other causes of tertiary adrenal insufficiency
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/addisons-disease-global-market-report
Which firms are leading the addison’s disease market?
Major companies operating in the addison’s disease market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz, Ipsen S.A., Neurocrine Biosciences Inc., Recipharm AB, Accord Healthcare, Eton Pharmaceuticals, DuoCort Pharma, Diurnal Group plc, Roxane Laboratories Inc.
How will industry trends affect the trajectory of the addison’s disease market?
Major companies operating in the addison’s disease market are focusing on innovations such as regenerative therapies to enhance treatment options, improve patient outcomes, and potentially reduce lifelong dependence on hormone replacement therapies by stimulating the body’s natural adrenal function. Regenerative therapies refer to medical approaches aimed at replacing or regenerating human cells, tissues, or organs to restore normal function and promote healing in cases of injury, disease, or degeneration. For instance, in July 2024, Eton Pharmaceuticals, Inc., a US-based public pharmaceutical company that focuses on developing and commercializing innovative treatments for rare diseases, announced the FDA’s acceptance of its New Drug Application (NDA) for ET-400, a proprietary formulation of hydrocortisone oral solution. ET-400 is easier to store and transport compared to other formulations that may require refrigeration. The liquid format addresses the needs of young patients who may have difficulty swallowing traditional tablets and allows for precise dosing.
Which geographic trends are shaping the addison’s disease market, and which region has the highest market share?
North America was the largest region in the addison’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the addison’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Addison’s Disease Market Report 2025 Offer?
The addison’s disease market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Addison’s disease is a rare disorder where the adrenal glands produce insufficient amounts of cortisol and aldosterone due to damage, caused by an autoimmune response. Symptoms include fatigue, muscle weakness, weight loss, low mood, and skin changes. Lifelong hormone replacement therapy is required to manage the condition and prevent severe complications such as adrenal crisis.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21084
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
